
Sign up to save your podcasts
Or


After surgery, many people with stage I to stage III hormone receptor-positive breast cancer take tamoxifen or an aromatase inhibitor for five to 10 years. This has been the standard of care for the last 25 years.
At the 2025 San Antonio Breast Cancer Symposium, UCLA scientist Dr. Aditya Bardia presented results on giredestrant, a new oral selective estrogen degrader/downregulator (SERD) that offered better disease-free survival — how long people live without the cancer returning – than tamoxifen or an aromatase inhibitor.
Listen to the episode to hear Dr. Bardia explain:
By Breastcancer.org4.3
4343 ratings
After surgery, many people with stage I to stage III hormone receptor-positive breast cancer take tamoxifen or an aromatase inhibitor for five to 10 years. This has been the standard of care for the last 25 years.
At the 2025 San Antonio Breast Cancer Symposium, UCLA scientist Dr. Aditya Bardia presented results on giredestrant, a new oral selective estrogen degrader/downregulator (SERD) that offered better disease-free survival — how long people live without the cancer returning – than tamoxifen or an aromatase inhibitor.
Listen to the episode to hear Dr. Bardia explain:

21,973 Listeners

43,680 Listeners

697 Listeners

11,852 Listeners

3,348 Listeners

2,634 Listeners

8,555 Listeners

52 Listeners

134 Listeners

4,865 Listeners

41,531 Listeners

20,517 Listeners

11,495 Listeners

320 Listeners

1,025 Listeners